MDxHealth SA
MDXH3.530USD
+0.130+3.82%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
174.73MMarket Cap
LossP/E TTM
More Details of MDxHealth SA Company
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
MDxHealth SA Info
Ticker SymbolMDXH
Company nameMDxHealth SA
IPO dateJun 26, 2006
CEOMr. Michael K. McGarrity
Number of employees312
Security typeOrdinary Share
Fiscal year-endJun 26
AddressCAP Business Center
CityHERSTAL
Stock exchangeNASDAQ Capital Market Consolidated
CountryBelgium
Postal code4040
Phone3243642070
Websitehttps://mdxhealth.com/
Ticker SymbolMDXH
IPO dateJun 26, 2006
CEOMr. Michael K. McGarrity
Company Executives of MDxHealth SA
Name
Name/Position
Position
Shareholding
Change
Mr. Michael K. McGarrity
Mr. Michael K. McGarrity
Chief Executive Officer, Director
Chief Executive Officer, Director
95.00K
--
Mr. Michael Holder
Mr. Michael Holder
Director
Director
--
--
Mr. Mark Shaffar
Mr. Mark Shaffar
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Thibodeau
Mr. Christopher (Chris) Thibodeau
Executive Vice President & U.S. Chief Operations Officer
Executive Vice President & U.S. Chief Operations Officer
--
--
Dr. Sanford S Siegel, M.D.
Dr. Sanford S Siegel, M.D.
Director
Director
--
--
Mr. Joseph (Joe) Sollee
Mr. Joseph (Joe) Sollee
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Mr. John Bellano
Mr. John Bellano
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Rudi Marien
Mr. Rudi Marien
Non-Executive Director
Non-Executive Director
--
--
Mme. Ruth Devenyns
Mme. Ruth Devenyns
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Walter M. (Wally) Narajowski
Mr. Walter M. (Wally) Narajowski
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael K. McGarrity
Mr. Michael K. McGarrity
Chief Executive Officer, Director
Chief Executive Officer, Director
95.00K
--
Mr. Michael Holder
Mr. Michael Holder
Director
Director
--
--
Mr. Mark Shaffar
Mr. Mark Shaffar
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher (Chris) Thibodeau
Mr. Christopher (Chris) Thibodeau
Executive Vice President & U.S. Chief Operations Officer
Executive Vice President & U.S. Chief Operations Officer
--
--
Dr. Sanford S Siegel, M.D.
Dr. Sanford S Siegel, M.D.
Director
Director
--
--
Mr. Joseph (Joe) Sollee
Mr. Joseph (Joe) Sollee
Executive Vice President, Chief Compliance Officer, General Counsel
Executive Vice President, Chief Compliance Officer, General Counsel
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States of America
69.71M
99.31%
Europe
476.00K
0.68%
Rest of the world
9.00K
0.01%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bleichroeder LP
14.91%
AWM Investment Company, Inc.
10.55%
MVM Partners LLP
9.50%
Lytton (Laurence W)
6.36%
Genomic Health, Inc.
4.93%
Other
53.75%
Shareholders
Shareholders
Proportion
Bleichroeder LP
14.91%
AWM Investment Company, Inc.
10.55%
MVM Partners LLP
9.50%
Lytton (Laurence W)
6.36%
Genomic Health, Inc.
4.93%
Other
53.75%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.60%
Investment Advisor/Hedge Fund
14.94%
Venture Capital
9.52%
Individual Investor
6.67%
Corporation
4.93%
Hedge Fund
1.21%
Research Firm
0.12%
Other
42.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
71
22.89M
46.25%
-1.34M
2025Q3
49
21.80M
44.04%
-2.18M
2025Q2
45
28.07M
56.71%
+2.44K
2025Q1
47
29.82M
60.25%
-710.83K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bleichroeder LP
7.38M
14.91%
--
--
Sep 30, 2025
AWM Investment Company, Inc.
5.22M
10.55%
--
--
Sep 30, 2025
MVM Partners LLP
4.70M
9.5%
--
--
Sep 30, 2025
Lytton (Laurence W)
3.15M
6.36%
-799.84K
-20.25%
Sep 30, 2025
Genomic Health, Inc.
2.44M
4.93%
+1.50M
+159.38%
Sep 27, 2024
Samjo Capital, LLC
1.45M
2.92%
-89.90K
-5.86%
Sep 30, 2025
Perkins Capital Management, Inc.
1.40M
2.83%
-17.42K
-1.23%
Sep 30, 2025
Kennedy Capital Management LLC
392.65K
0.79%
+344.85K
+721.41%
Sep 30, 2025
Northern Trust Global Investments Limited
305.07K
0.62%
-106.86K
-25.94%
Sep 30, 2025
FreeGulliver LLC
252.89K
0.51%
+129.35K
+104.70%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.04%
iShares Micro-Cap ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
